Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC) Meeting Abstract
| Authors: | Hendifar, A. E.; Rosen, L. S.; Cercek, A.; McRee, A. J.; Mallick, A. B.; Spigel, D. R.; Tavazoie, S. F.; Rowinsky, E. K.; Szarek, M.; Gonsalves, F.; Kurth, I.; Andreu, C.; Busby, R.; Spector, S.; Darst, D. M.; Lebaka, N.; Bechar, N.; Tavazoie, M.; Wasserman, R.; Fakih, M. |
| Abstract Title: | Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC) |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680301120 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.3579 |
| Notes: | Meeting Abstract: 3579 -- Meeting also held virtually -- Source: Wos |
